Table 3.
Potentially Inappropriate Prescriptions at Baseline in Intervention and Control Groups
| Potentially Inappropriate Prescription | Intervention Group, No. (%) (n = 99) | Control Group, No. (%) (n = 97) |
|---|---|---|
| Proton pump inhibitor at maximum therapeutic dosage for >8 weeks | 53 (53.3) | 65 (67.7) |
| NSAIDs: long-term use, interactions with certain medications (eg, diuretic) | 21 (21.2) | 16 (16.8) |
| Therapeutic duplication: any regular duplicate drug class prescription (eg, 2 concurrent opiates, NSAIDs) | 19 (19.2) | 13 (13.5) |
| Long-term use (>1 month) of long-acting benzodiazepines | 14 (14.4) | 8 (8.3) |
| Steroid without bisphosphonate | 9 (9.1) | 4 (4.2) |
| Bladder antimuscarinics: contraindications and interactions with certain medications | 1 (1.0) | 9 (9.4) |
| Prolonged use (>1 week) of first-generation antihistamines | 4 (4.0) | 2 (2.1) |
| Tricyclic antidepressants: contraindications and interactions with certain medications (eg, opiate, calcium channel blocker) | 1 (1.0) | 5 (5.2) |
| Thiazide diuretic in patient with gout | 3 (3.0) | 2 (2.1) |
| Aspirin: contraindications and interactions with certain medications (eg, warfarin) | 3 (3.0) | 1 (1.0) |
| Digoxin: inappropriate dose | 1 (1.0) | 3 (3.1) |
| Calcium channel blocker: contraindications and interactions with certain medications | 0 (0.0) | 3 (3.1) |
NSAID = nonsteroidal anti-inflammatory drug.